ANPEP and neoplasm: Through NGR-to-isoDGR rearrangement NGR-peptides are able to bind to both CD13 and RGD binding integrin, which is why these peptides are considered ideal candidates for selective, dual acting, tumor targeting ligands (Fig 1).